Rituximab for rheumatoid arthritis
Referencias
Additional references
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis & Rheumatism 1988;31(3):315‐24.
Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis & Rheumatism 2006;54(1):26‐37.
Visual Rx version 2.0. Dr. Christopher Cates EBM website. Available from: URL: http://www.nntonline.net/. Email: [email protected].
Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti‐tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks. Arthritis & Rheumatism 2006;54(9):2793‐806.
Dörner T, Burmester GR. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Current Opinion in Rheumatology 2003;15(3):246‐52.
Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205‐11.
Edwards JC, Szczepanski L, Szechinski J, Filipowicz‐Sosnowska A, Emery P, Close DR, et al. Efficacy of B‐cell‐targeted therapy with rituximab in patients with rheumatoid arthritis. New England Journal of Medicine 2004;350:2572‐81.
Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis & Rheumatism 1995;38(6):727‐35.
Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long‐term disability in patients with rheumatoid arthritis by disease‐modifying antirheumatic drug‐based treatment strategies. Arthritis & Rheumatism 1996;39(4):616‐22.
Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. European Journal of Radiology 1998;27(Suppl 1):S18‐24.
Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti‐tumor necrosis factor alpha treatment. The Journal of Rheumatology 2005;32:2109‐15.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated February 2008]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org2008.
Larsen A. Radiological grading of rheumatoid arthritis: an interobserver study. Scandinavian Journal of Rheumatology 1973;2:136‐8.
Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti‐Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. New England Journal of Medicine 2000;343(22):1594‐602.
Mohrbacher A. B cell non‐Hodgkin's lymphoma: rituximab safety experience. Arthritis Research & Therapy 2005;7(Suppl 3):S19‐5.
Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. New England Journal of Medicine 2004;350(21):2167‐79.
Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty‐eight‐joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism 1995;38(1):44‐8.
van der Heijde DM. How to read radiographs according to the Sharp/van der Heijde method. The Journal of Rheumatology 1999;26:743‐5.
Wolfe F. The natural history of rheumatoid arthritis. The Journal of Rheumatology 1996;44(Suppl):13‐22.
